Straits Times Index
3,292.69 +10.64 (+0.32%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
58,190.24 -2,556.55 (-4.21%) CMC Crypto 200
1,275.94 -63.12 (-4.72%)
Aurinia Pharmaceuticals Inc. (AUPH)
After hours:
| Previous close | 5.09 |
| Open | 5.08 |
| Bid | 5.18 x 1000 |
| Ask | 5.22 x 1000 |
| Day's range | 5.07 - 5.30 |
| 52-week range | 4.71 - 12.43 |
| Volume | |
| Avg. volume | 2,096,363 |
| Market cap | 752.014M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.29 |
Business WireAurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
ROCKVILLE, Md. & EDMONTON, Alberta, May 01, 2024--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
Business WireThe U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
ROCKVILLE, Md. & EDMONTON, Alberta, April 30, 2024--The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
Business WireUPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
ROCKVILLE, Md. & EDMONTON, Alberta, April 16, 2024--UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
